InvestSMART

Medical Developments International Limited (ASX:MVP)

ALERT: Price-sensitive ASX Announcement for MVP
Current share price for MVP : $0.485 -0.03 (-5.83%)+
Announcement
Release
20 Aug 2026 8:55AM
Price at Release
$0.515
Full Release
download
Summary
Medical Developments International Limited (MVP) reported its FY26 financial results for the year ended 30 June 2026. The company saw an increase in revenue to $42.568 million, up from $39.056 million in the previous year. This growth was primarily driven by the Pain Management segment, which contributed $31.620 million to the overall revenue. The respiratory segment's revenue was $10.948 million. MVP's EBITDA for FY26 was $2.900 million, a slight decrease from the previous year's $3.155 million. The net profit after tax stood at $626,000, significantly up from $94,000 in FY25. The company's net assets increased to $55.807 million, and cash and cash equivalents decreased to $14.368 million due to investing activities, including a $7 million term deposit. Despite these financial movements, MVP is focused on managing operational efficiency and strengthening its balance sheet.
Key Points
  • Revenue increased to $42.568 million in FY26.
  • Pain Management segment contributed $31.620 million.
  • Respiratory segment revenue was $10.948 million.
  • EBITDA for FY26 was $2.900 million.
  • Net profit after tax was $626,000.
  • Net assets increased to $55.807 million.
  • Cash and cash equivalents decreased to $14.368 million due to investing activities.
  • Focus on operational efficiency and balance sheet strength.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.